BTS GUIDELINES

BTS recommendations for assessing risk and for managing *Mycobacterium tuberculosis* infection and disease in patients due to start anti-TNF-α treatment

British Thoracic Society Standards of Care Committee*

Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor α (anti-TNF-α) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.

In view of the increased risk of reactivation of tuberculosis (TB) with anti-tumour necrosis factor α (anti-TNF-α) treatment, various professional groups have sought the advice of the Joint Tuberculosis Committee of the British Thoracic Society. The objectives of these guidelines are to quantify these risks and to give advice on the treatment of TB disease and infection in patients being assessed for anti-TNF-α treatment. The risks and benefits of treatment for latent TB infection in those unsuitable for tuberculin skin testing are also covered. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.

### 1. INTRODUCTION

#### 1.1 Structure of the recommendations

The format follows that used for other BTS guidelines. At the start there is a summary of the abstracted bullet points from each section. Following that there is an algorithm summarising the management of patients due to start anti-TNF-α treatment (fig 1). The recommendations use the revised Scottish Intercollegiate Guidelines Network (SIGN) grading system available at [http://www.sign.ac.uk/guidelines/fulltext/50/section6.html](http://www.sign.ac.uk/guidelines/fulltext/50/section6.html) (table 1). The primary source literature has been individually graded for its methodology (where appropriate) and the grading is given alongside the reference using the revised SIGN levels of evidence (table 2).

#### 1.2 Methodology for the generation of the recommendations

The initial systematic literature search (Pubmed, EMBASE) was carried out by one of the

*Members of the BTS Standards of Care Subcommittee: LP Ormerod (Chair), H J Milburn, S Gillespie, J Ledingham, D Rampton.

---

**Table 1 Revised SIGN grading system: grades of recommendation**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At least one meta-analysis, systematic review, or RCT rated as 1** and directly applicable to the target population; or A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1** directly applicable to the target population and demonstrating overall consistency of results.</td>
</tr>
<tr>
<td>B</td>
<td>A body of evidence including studies rated as 2** directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1** or 1*.</td>
</tr>
<tr>
<td>C</td>
<td>A body of evidence including studies rated as 2** directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2**.</td>
</tr>
<tr>
<td>D</td>
<td>Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2**.</td>
</tr>
</tbody>
</table>

**Table 2 Revised SIGN grading system: levels of evidence**

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1**</td>
<td>High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias.</td>
</tr>
<tr>
<td>1*</td>
<td>Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias.</td>
</tr>
<tr>
<td>1-</td>
<td>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias.</td>
</tr>
<tr>
<td>2**</td>
<td>High quality systematic reviews of case-control or cohort studies, High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal.</td>
</tr>
<tr>
<td>2*</td>
<td>Well conducted case-control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal.</td>
</tr>
<tr>
<td>2-</td>
<td>Case-control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal.</td>
</tr>
<tr>
<td>3</td>
<td>Non-analytical studies (e.g. case reports, case series).</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion.</td>
</tr>
</tbody>
</table>
Abstracted bullet points

- In patients receiving anti-TNF-α treatment there is an increased risk of clinical tuberculosis (TB) developing.
- Patients should have a clinical examination, their history of any prior TB treatment checked, a chest radiograph and, if appropriate, a tuberculin test (see text). Any patient with an abnormal chest radiograph or previous history of TB or TB treatment should be referred for assessment by a specialist with an interest in TB. (D)
- Patients with an abnormal chest radiograph and/or symptoms raising a suspicion of TB should be thoroughly investigated to exclude active disease. (D)
- Any patient with active TB, either pulmonary or non-pulmonary, should receive standard chemotherapy. (A)
- Patients with active TB should receive a minimum of 2 months full chemotherapy directed by a specialist in TB before starting anti-TNF-α treatment. (D)
- Patients with an abnormal chest radiograph consistent with past TB, or a history of prior extrapulmonary TB but who have received previous adequate treatment, should be monitored regularly. (D)
- Active TB should be excluded by appropriate investigations in patients with an abnormal chest radiograph, or a history of prior pulmonary or extrapulmonary TB not previously adequately treated. Chemoprophylaxis should be given before commencing anti-TNF-α treatment. (A)
- For patients with a normal chest radiograph who are not on immunosuppressive therapy, a tuberculin test is helpful in management: an algorithm is supplied. (D)
- For those with a normal chest radiograph who are on immunosuppressive therapy, a tuberculin test will not be helpful and need not be undertaken. An individual risk assessment should be made (tables 3–5); if the annual risk of TB is greater than the risk of drug induced hepatitis, then chemoprophylaxis should be given. (C) If the risk of hepatitis is greater, the patient should be monitored regularly with suggestive symptoms promptly investigated to permit early diagnosis of active disease. An algorithm is supplied. (C) In general, black African patients aged over 15 years and all South Asians born outside the UK should be considered for chemoprophylaxis with isoniazid for 6 months (6H).
- Close cooperation between clinicians prescribing anti-TNF-α and specialists in the management of TB is strongly recommended. (D)

Committee

Abstracted bullet points

1.3 Conflict of interest

All members of the Guideline Committee were asked to submit a written record of possible conflicts of interest to the Standards of Care Committee of the BTS. None were recorded.

1.4 Suggested review date

The Guidelines Committee suggest that the guidelines should be reviewed in summer 2008.

2. BACKGROUND

2.1 The need for recommendations

The increase in active TB associated with anti-TNF treatment has led to a requirement to screen for active and latent TB in patients before anti-TNF-α treatment is given. This screening, suggested by manufacturers to include tuberculin skin testing, is further complicated by the fact that many patients—up to 79% in the infliximab study1—were receiving immunosuppressive therapy such as maintenance prednisolone, azathioprine, 6-mercaptopurine, methotrexate, cyclophosphamide, cyclosporine, tacrolimus, or mycophenolate mofetil which would interfere with the accuracy of tuberculin skin testing.2 The product licence for infliximab states that the product should be used in conjunction with methotrexate or other immunosuppressants, and in practice the other anti-TNF agents would also normally be used with other immunosuppressants. Chemoprophylaxis or preventive treatment for TB itself carries a small risk, with drug induced hepatitis being the main issue, increasing with age and occasionally fatal. It is also important to exclude active TB disease before chemoprophylaxis is given, particularly as single agent chemoprophylaxis given when active disease is present could lead to the development of drug resistance. These problems have led to many requests for advice in this area.

2.2 Background epidemiology

Infliximab, a murine human chimeral monoclonal antibody against TNF-α, is approved in the USA and Europe for the treatment of rheumatoid arthritis4 and Crohn’s disease5 and ankylosing spondylitis. Etanercept is a fusion protein that binds free TNF-α using the soluble portion of tumour necrosis factor receptor 2 (TNFR2) coupled with an Fc moiety,6 and is also used in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthropathy, and juvenile idiopathic arthritis. Adalimumab, a recombinant fully humanised monoclonal antibody against TNF, became licensed for the treatment of rheumatoid arthritis in September 2003.7 Post-marketing surveillance in the USA and beyond to the end of May 2001 showed 70 cases of TB associated with infliximab use and a much lower number of cases with etanercept.8 Cases of TB have also been described with

www.thoraxjnl.com
adalimumab. The majority of the cases of TB in patients given infliximab occurred within three cycles of treatment, with a median of 12 weeks after commencing treatment.7 The frequency of tuberculosis was much higher than other opportunistic infections reported with the drug, and was higher than reported background rates.9 Over 50% of reported TB cases associated with anti-TNF-α treatment are extra-pulmonary.9 The number of cases of TB reported to the US Food and Drugs Administration had risen to 117 by December 2001, giving a recalculated TB prevalence of 41/100 000 in infliximab/etanercept treated patients in the USA with rheumatoid arthritis, 9/100 000 in patients in the USA with Crohn’s disease, and 224/100 000 in all non-USA patients with rheumatoid arthritis or Crohn’s disease.10 The number of TB cases now reported has reached 242 (Keane J, personal communication, 2004), but the curve has levelled off due to either improved TB risk assessment, tuberculin testing and isoniazid prophylaxis, and/or reporting fatigue.

The estimated prevalence of TB in rheumatoid arthritis patients in the USA is 6.2/100 000 (95% CI 1.6 to 34);11 in patients receiving infliximab the prevalence was originally 24.4/100 000,1 approximately a fourfold increase. In a second part of the prevalence study11 the incidence of TB in infliximab treated patients was 52.5/100 000 (95% CI 14.3 to 134.4), an approximate eightfold increase, but this was based on only a very small number of TB cases. Overall, the subcommittee believes that there is an average fivefold increased risk of TB with anti-TNF-α treatment.

3. RISKS OF TUBERCULOSIS AND OF DRUG INDUCED HEPATITIS FROM CHEMOPROPHYLAXIS

3.1 Risks of TB
The incidence of TB varies markedly within the United Kingdom (UK) according to a number of factors.12 13 These are age, ethnic group and, for those not born in the UK, the length of time since first entry. Where possible, data on the current annual risk of TB have been updated from those derived from continuous enhanced surveillance (tables 3–5).

Calculation of the risk of TB is as follows (see also table 5):

- If white and UK born, use data from table 3.
- If Indian subcontinent (ISC), use table 4.
Table 3  Annual risk of TB disease/100 000 in England and Wales: effect of age (to the nearest whole number)

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>White</th>
<th>Black African</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–14</td>
<td>1</td>
<td>47</td>
</tr>
<tr>
<td>15–34</td>
<td>2</td>
<td>314</td>
</tr>
<tr>
<td>35–54</td>
<td>4</td>
<td>168</td>
</tr>
<tr>
<td>55–74</td>
<td>7</td>
<td>204</td>
</tr>
<tr>
<td>&gt;75</td>
<td>11</td>
<td>Not available</td>
</tr>
</tbody>
</table>


Table 4  Annual risk of TB disease/100 000 in England and Wales: effect of place of birth/duration of residence in England and Wales

<table>
<thead>
<tr>
<th>Age</th>
<th>Place of birth</th>
<th>Years after first entry</th>
<th>All patient rate</th>
<th>ISC ethnic rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–14</td>
<td>UK</td>
<td></td>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Abroad</td>
<td></td>
<td>31</td>
<td>88</td>
</tr>
<tr>
<td>15+</td>
<td>UK</td>
<td>0–4</td>
<td>4</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Abroad</td>
<td>5+</td>
<td>180</td>
<td>540</td>
</tr>
<tr>
<td>35+</td>
<td>Abroad</td>
<td>0–4</td>
<td>53</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5+</td>
<td>146</td>
<td>593</td>
</tr>
</tbody>
</table>


Table 5  Sample calculations based on data in tables 3 and 4

<table>
<thead>
<tr>
<th>Case type</th>
<th>Annual risk of TB disease/100 000</th>
<th>TB risk adjusted for anti-TNF effect</th>
<th>Risks of prophylaxis/100 000 (table 6)</th>
<th>Risk/benefit conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>Age 55–74 UK born</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISC</td>
<td>Age &gt;35 In UK 3 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black African</td>
<td>Age 35–54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other ethnic</td>
<td>Age 35+ In UK &gt;5 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>35</td>
<td>278</td>
<td>Observation</td>
</tr>
</tbody>
</table>

The weighted average risk for prophylaxis with isoniazid (6H) is 278/100 000 which is used for these calculations. The weighted average risk for rifampicin/isoniazid (3RH) is higher at 1766/100 000, but this regimen may need to be considered if a shorter duration of chemoprophylaxis is needed on clinical grounds (see section 4.6).

3.2 Risks of drug induced hepatitis from TB chemoprophylaxis

A database search (Medline and Embase) was carried out on the reported hepatotoxicity of antituberculosis chemoprophylaxis from 1966 to 2002 in adults. Children were excluded because they have a very low rate of drug reactions, and studies in HIV positive individuals were excluded because such individuals have a higher than normal drug reaction profile. The hepatitis rates for various regimens were derived from these data (table 6).

Only hepatitis sufficient to stop treatment (symptomatic) or grade 3 alanine transferase (ALT 5–20 times normal) or grade 4 (ALT >20 times normal) hepatitis is reported here. According to the manufacturers, the use of anti-TNF treatment is contraindicated if there is co-infection with HIV, hepatitis B or C, so this guidance does not apply to patients with these co-infections.

4. RECOMMENDATIONS

4.1 Assessment before anti-TNF treatment

Patients should have a clinical examination, their history of any prior TB treatment checked, a chest radiograph and, if indicated, a tuberculin test (sections 4.4 and 4.5). Any patient with an abnormal chest radiograph or previous history of TB or TB treatment should be referred to a specialist with an interest in TB, either a thoracic or infectious disease physician. Close cooperation between specialists with an interest in TB, either a thoracic or infectious disease physician, can start anti-TNF treatment but should be monitored clinically every 3 months with

4.2 Active TB found before anti-TNF-α treatment

Patients with chest radiographic abnormalities (such as infiltrates, cavitation, pleural effusion or mediastinal lymphadenopathy) and/or symptoms raising a suspicion of TB should be thoroughly investigated to exclude active disease. This should include sputum microscopy and culture for acid-fast bacilli and, if indicated, bronchoscopy and washings and biopsy and culture of pleura and/or mediastinum. Extrapulmonary sites may require material to be obtained by aspiration for culture or biopsy for culture and histological examination.

Any person with active TB, either pulmonary or non-pulmonary, should receive standard chemotherapy. (A) Anti-TNF-α treatment should not be commenced for at least 2 months after antituberculosis treatment with full compliance has begun, supervised by a thoracic physician or infectious disease specialist, and until the drug susceptibility profile of the organism in those with positive cultures is known, as a minimum. (D) Ideally, it would be preferable to delay anti-TNF treatment until completion of a full course of antituberculosis treatment. (D)

4.3 Inactive TB found before anti-TNF-α treatment

(a) Previous adequate treatment

Patients with an abnormal chest radiograph consistent with past TB or a history of prior extrapulmonary TB who have received previous adequate treatment, as judged by a thoracic or infectious disease physician, can start anti-TNF-α treatment but should be monitored clinically every 3 months with

- If black African, use table 3 (similar data to table 4 not yet available).
- If either white, non-UK born, or other ethnic group, use “All patient rate” in table 4.
- If in doubt or in special circumstances, consult local thoracic physician.
Chapter 4: Chemoprophylaxis

4.6 Chemoprophylaxis

There are two potential chemoprophylaxis regimens: isoniazid for 6 months (6H) or rifampicin plus isoniazid for 3 months (3RH). Rifampicin and pyrazinamide for 2 months (2RZ) was a regimen used in the USA, but it had a very high rate of hepatitis (table 6) with a number of fatalities reported. Accordingly, the choice of regimen is between 6H which has a lower hepatitis rate and 3RH which may have advantages in terms of shorter duration and thus possibly better adherence (table 5) and also less risk of drug resistance developing if active disease is present.

The decision on the chemoprophylaxis regimen should be made by the thoracic or infectious disease physician following informed discussion with both the patient and the referring clinician.

In contrast to patients falling into category 4.3b (above), chemoprophylaxis for patients with a normal chest radiograph not assessable by tuberculin skin test can start concurrently with anti-TNF treatment. If the chemoprophylaxis regimen contains rifampicin, any maintenance dose of prednisolone should be doubled for its duration and note made of interactions with other immunosuppressive agents such as tacrolimus and cyclosporine.

It should be noted that no chemoprophylaxis regimen is wholly effective; protective efficacies of 60% have been reported for 6H and of 50% for 3RH. If patients who have had chemoprophylaxis develop symptoms suggestive of clinical TB, they should be promptly and appropriately investigated.
4.7 Management of clinical TB developing during anti-TNF-α treatment

Patients who develop active TB while on anti-TNF-α treatment should receive full antituberculosis chemotherapy.15 (A) In these circumstances, which are different from TB disease diagnosed before anti-TNF-α treatment has started, the anti-TNF-α treatment can be continued if clinically indicated because the patient would otherwise be prevented from receiving the continued clinical benefit to their underlying disease and may have a flare up or major clinical deterioration. (D) Although there are no good data in this area, it is known that HIV positive individuals with reduced CD4 counts and clinical TB, who are even more immunosuppressed than those on anti-TNF-α treatment, respond just as well to TB treatment as those who are HIV negative.14

5. SUGGESTED AUDIT CRITERIA

Suggested audit criteria are as follows.

- History of previous TB checked? (Y/N)
- Chest radiograph within 3 months of starting anti-TNF-α treatment? (Y/N)
- Chest radiograph normal? (Y/N)
- If abnormal, referred to TB specialist? (Y/N)
- If no, referred for risk stratification? (Y/N)
- If skin test performed, is it positive? (Y/N)
- If no, referred for risk stratification? (Y/N)
- Tuberculin skin test possible before treatment? (Y/N)
- If abnormal, referred to TB specialist? (Y/N)
- Chest radiograph normal? (Y/N)
- If risk stratification performed, given treatment for latent TB infection? (Y/N)

Authors’ affiliations

L P Ormerod, Consultant Chest Physician, Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, UK
H J Milburn, Consultant Chest Physician, Guy’s and St Thomas’ Hospitals, London SE1 9RT
S Gillespie, Consultant Microbiologist, Department of Medical Microbiology, Royal Free and University College Medical School, London NW3 2PF
J Ledingham, Consultant Rheumatologist, Queen Alexandra Hospital, Portsmouth PO6 3LY (representing the British Society of Rheumatology)
D Rampton, Consultant Gastroenterologist, Barts and the London NHS Trust, London E1 1BB (representing the British Society of Gastroenterology)

REFERENCES